Program
SPGL008
A development code.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms, led by 3SBio.
Furthest: phase 2, since Feb 5, 20263 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 3SBio | 33 open or running | phase 2since Feb 5, 2026 | Jun 17, 2025 | Nov 2027phase 2 · NCT07874984 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2025First study: phase 1 study in Advanced Malignant TumorsFirst studyNCT07038005 · 96 planned · China
- Feb 5, 2026Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsPhase 2 reachedNCT07445308 · 120 planned
- Sep 20, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984 · 220 planned
Ahead
- Nov 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984
- Nov 21, 2028Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT07445308
TargetBeta
“SPGL008 is a dual-functional molecule that combines an anti-B7-H3 monoclonal antibody with IL-15Rα sushi / IL-15.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nogapendekin alfa inbakiceptrule | ImmunityBio | phase 3 | 45 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07874984Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | Nov 2027 | 220 |
| NCT07445308Non-Muscle Invasive Bladder Neoplasms | 2 | Not yet recruiting | Nov 21, 2028 | 120 |
| NCT07038005Advanced Malignant Tumors · China | 1 | Recruiting | Sep 22, 2026 | 96 |
How it is read
Names in the registry
- “SPGL008”, 3 entries
Codes read as this program: SPGL008.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Non-Muscle Invasive Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.